NO953329L - Rekombinante viruser og deres anvendelse i genterapien for behandling av öyesykdommer - Google Patents

Rekombinante viruser og deres anvendelse i genterapien for behandling av öyesykdommer

Info

Publication number
NO953329L
NO953329L NO953329A NO953329A NO953329L NO 953329 L NO953329 L NO 953329L NO 953329 A NO953329 A NO 953329A NO 953329 A NO953329 A NO 953329A NO 953329 L NO953329 L NO 953329L
Authority
NO
Norway
Prior art keywords
eye diseases
treatment
gene therapy
recombinant viruses
diseases
Prior art date
Application number
NO953329A
Other languages
English (en)
Other versions
NO953329D0 (no
NO319571B1 (no
Inventor
Pascale Briand
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of NO953329L publication Critical patent/NO953329L/no
Publication of NO953329D0 publication Critical patent/NO953329D0/no
Publication of NO319571B1 publication Critical patent/NO319571B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO19953329A 1993-03-03 1995-08-24 Anvendelse av et defektivt, rekombinant adenovirus. NO319571B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302438A FR2702152B1 (fr) 1993-03-03 1993-03-03 Virus recombinants et leur utilisation en thérapie génique.
PCT/FR1994/000220 WO1994020146A1 (fr) 1993-03-03 1994-02-28 Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires

Publications (3)

Publication Number Publication Date
NO953329L true NO953329L (no) 1995-08-24
NO953329D0 NO953329D0 (no) 1995-08-24
NO319571B1 NO319571B1 (no) 2005-08-29

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19953329A NO319571B1 (no) 1993-03-03 1995-08-24 Anvendelse av et defektivt, rekombinant adenovirus.

Country Status (15)

Country Link
EP (1) EP0687184B1 (no)
JP (1) JP3835809B2 (no)
AT (1) ATE220923T1 (no)
AU (1) AU693782B2 (no)
CA (1) CA2154355A1 (no)
DE (1) DE69431046T2 (no)
DK (1) DK0687184T3 (no)
ES (1) ES2181710T3 (no)
FR (1) FR2702152B1 (no)
HU (1) HU218900B (no)
NO (1) NO319571B1 (no)
NZ (1) NZ262135A (no)
PT (1) PT687184E (no)
WO (1) WO1994020146A1 (no)
ZA (1) ZA941426B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2718150B1 (fr) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
DE60022549T2 (de) * 1999-12-30 2006-05-18 Aventis Pharma S.A. Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
NZ546983A (en) 2003-11-24 2009-05-31 Canji Inc Reduction of dermal scarring
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
HRP20180154T1 (hr) 2010-08-06 2018-03-09 Genzyme Corporation Pripravci vegf antagonista i njihova uporaba

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434750B1 (en) * 1988-09-13 1997-07-09 Biosource Technologies, Inc. Medicament for treating degenerative diseases of the nervous system
JPH06506599A (ja) * 1991-04-05 1994-07-28 エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー パッケージング配列に相補的なアンチセンス核酸によるレトロウイルスの抑制

Also Published As

Publication number Publication date
WO1994020146A1 (fr) 1994-09-15
ES2181710T3 (es) 2003-03-01
EP0687184A1 (fr) 1995-12-20
PT687184E (pt) 2002-12-31
NO953329D0 (no) 1995-08-24
HU218900B (hu) 2000-12-28
FR2702152A1 (fr) 1994-09-09
ATE220923T1 (de) 2002-08-15
CA2154355A1 (fr) 1994-09-15
NO319571B1 (no) 2005-08-29
DE69431046D1 (de) 2002-08-29
FR2702152B1 (fr) 1995-05-24
AU693782B2 (en) 1998-07-09
AU6144494A (en) 1994-09-26
ZA941426B (en) 1994-10-04
HU9502573D0 (en) 1995-10-30
NZ262135A (en) 2000-12-22
JP3835809B2 (ja) 2006-10-18
DE69431046T2 (de) 2003-02-13
HUT73215A (en) 1996-06-28
JPH08509208A (ja) 1996-10-01
DK0687184T3 (da) 2002-10-28
EP0687184B1 (fr) 2002-07-24

Similar Documents

Publication Publication Date Title
NO953329D0 (no) Rekombinante viruser og deres anvendelse i genterapien for behandling av öyesykdommer
FR2705361B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
AU586860B2 (en) Therapeutical application of phosphonylmethoxyalkyl adenines
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
NO883896D0 (no) Konjugater av cytokiner med immunglobuliner.
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE69635173D1 (de) Rekombinante MVA Viren und deren Verwendung
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
DK19488A (da) Bestraalingsandordning til brug ved medicinsk behandling af naese- og halspassager
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
FI924475A7 (fi) Trinitrobentseenien tai karmiinihapon käyttö syövän ja virusperäisten sairauksien hoidossa
Dhillon et al. Photodynamic therapy
Dhillon et al. Local anaesthetic and vasoconstrictor agents used in ENT
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
UA12628A (uk) Спосіб лікуваhhя гострого вірусhого гепатиту